Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.
We designed the present case-control study in order to examine the validity of apolipoprotein (apo) A-I, B, apoB/apoA-I ratio and Lp(a) as alternative markers of cardiovascular morbidity in end-stage renal disease (ESRD) patients undergoing chronic hemodialysis (HD). Twenty-five HD patients (18 males, mean age 63, range 52-69 years) comprised the group with prevalent cardiovascular disease (CVD) and 50 HD patients (35 males, mean age 62, range 40-77 years) with non evident cardiovascular disease history constituted the second study group. Patients with CVD had significantly higher concentrations of serum apoB, apoB/apoA-I ratio and Lp(a), and lower levels of apoA-I compared to patients without incident CVD. All three parameters studied were correlated with cardiovascular morbidity, i.e. apoA-I negatively and apoB and apoB/apoA-I ratio positively (r = -0.6, P < 0.05; r = 0.659, P < 0.01; and r = 0.614, P < 0.01, respectively). Furthermore, logCRP exhibited as well a significant positive correlation with cardiovascular morbidity (r = 0.704, P < 0.001), not this being the case for Lp(a) which was not found to exhibit such a correlation (r = 0.05, P = NS). Among them, apoB and apoB/apoA-I ratio exhibited the characteristics most coherent to CVD. The age- and sex-adjusted OR for the presence of CVD was 2.3 and 2.0, respectively, which remained independent of any confounding effect of inflammation. In conclusion, serum apoB levels and apoB/apoA-I ratio exhibit characteristics of credible independent markers of in HD patients.
Kirmizis
Dimitrios
D
Department of Nephrology, Serres General Hospital, Serres, Greece.
Koutoupa
Evangelia
E
Tsiandoulas
Apostolos
A
Valtopoulou
Aphroditi
A
Niavis
Georgios
G
Markou
Phani
P
Barboutis
Konstantinos
K
Circulation. 2004 Jul 13;110(2):227-39
15249516
Atherosclerosis. 2003 Nov;171(1):145-55
14686332
Kidney Int. 2002 Jan;61(1):209-18
11786103
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):553-9
15618542
J Am Soc Nephrol. 1998 Dec;9(12 Suppl):S24-30
11443765
JAMA. 2004 Jan 28;291(4):451-9
14747502
Circulation. 2000 Feb 8;101(5):477-84
10662743
Circulation. 2004 Nov 2;110(18):2824-30
15492318
Diabetes Care. 2004 Aug;27(8):1991-7
15277429
QJM. 2006 May;99(5):277-87
16504986
Kidney Int. 2002 May;61(5):1887-93
11967041
Circulation. 2002 Mar 12;105(10):1162-9
11889008
Atherosclerosis. 2005 Apr;179(2):339-44
15777551
J Am Soc Nephrol. 1995 Jul;6(1):110-20
7579063
Atherosclerosis. 1983 Sep;48(3):279-88
6579964
Circulation. 2002 Nov 12;106(20):2526-9
12427645
Clin Chem Lab Med. 2004;42(12):1355-63
15576296
Circulation. 1992 Aug;86(2):475-82
1386292
J Lipid Res. 1994 May;35(5):779-92
8071601
Semin Dial. 2006 Jan-Feb;19(1):32-40
16423180
Circulation. 1998 Apr 21;97(15):1453-60
9576425
Arteriosclerosis. 1983 May-Jun;3(3):260-72
6573877
Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1918-23
12426225
Atherosclerosis. 1997 Jun;131(2):229-36
9199276
Circulation. 1999 May 18;99(19):2517-22
10330382
Am J Kidney Dis. 1990 May;15(5):458-82
2333868
N Engl J Med. 2005 Jul 7;353(1):46-57
16000355
Clin Nephrol. 1989 Feb;31(2):88-95
2920472
Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2408-13
11073845
J Am Soc Nephrol. 2003 Sep;14(9):2329-37
12937310
Circulation. 2000 Sep 5;102(10):1082-5
10973834
Lancet. 2001 Dec 15;358(9298):2026-33
11755609
Eur Heart J. 2005 Feb;26(3):271-8
15618061
JAMA. 2005 Jul 20;294(3):326-33
16030277
JAMA. 2001 May 16;285(19):2486-97
11368702
Circulation. 1996 Aug 1;94(3):273-8
8759066
Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3
11576918
J Hypertens. 1999 Feb;17(2):151-83
10067786
Clin Chem. 1995 Feb;41(2):246-55
7533064
Lancet. 2004 Sep 11-17;364(9438):937-52
15364185